Use of PD-L1 Biomarker in Second Line Therapy for Non-Small Cell Lung Cancer- Budget Impact Analysis from a Private Payer Perspective In Brazil
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.138
https://www.valueinhealthjournal.com/article/S1098-3015(18)30438-8/fulltext
Section Title :
Section Order :
790
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30438-8&doi=10.1016/j.jval.2018.04.138